All posts by: Michael Zand

Geovax Labs, Inc. (GOVX) Announces Collaboration with Vaxeal on Cancer Immunotherapy Program
StreetInsider.com
GeoVax Labs, Inc. (GOVX) announced today that it is collaborating with Vaxeal Holding SA on the expansion of GeoVax’s cancer immunotherapy program. GeoVax’s immuno-oncology program is based on its Modified Vaccinia Ankara (MVA) Virus-Like Particle (VLP …
GeoVax to Present During China Showcase at Biotech Showcase 2018Markets Insider

all 2 news articles »

GeoVax and Vaxeal to Collaborate on Cancer Immunotherapy Program
GlobeNewswire (press release)
ATLANTA, GA, Jan. 03, 2018 (GLOBE NEWSWIRE) — GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing human vaccines, announced today that it is collaborating with Vaxeal Holding SA on the expansion of GeoVax’s cancer immunotherapy program …

and more »

Inovio Amends Chinese Deal for Immunotherapy, Shares Up
Zacks.com
Per the amended agreement, ApolloBio will have the exclusive right to develop and commercialize Inovio’s DNA immunotherapy product, VGX-3100, within Greater China (China, Hong Kong, Macao, Taiwan). Currently, VGX-3100, which is an investigational …
Inovio grabs $23M through HPV immunotherapy licensing deal with China’s ApolloBioFiercePharma
Inovio Enters License and Collaboration Agreement with ApolloBio To Develop and Commercialize VGX-3100 in …Markets Insider
Could Inovio Pharmaceuticals, Inc. (INO) Rise Even More? The Stock Had Another Big Increase TodayFrisco Fastball
Market Exclusive
all 50 news articles »

Juravinski hospital offers new approach for stem cell transplants
HamiltonNews
It’s an approach aimed at enabling more stem cell transplant patients to stay at home rather in the hospital. Since last fall, the Juravinski Hospital and Cancer Centre (JHCC) has been treating autologous stem cell recipients who have had low doses of …

Inovio grabs $23M through HPV immunotherapy licensing deal with China’s ApolloBio
FiercePharma
China’s ApolloBio increased its upfront payment to obtain Greater China rights to Inovio’s HPV immunotherapy. Share Facebook Twitter LinkedIn Email Print. Inovio and China’s ApolloBio have agreed to tweak their exclusive licensing deal formed about a …
Inovio Amends Chinese Deal for Immunotherapy, Shares UpZacks.com
Inovio Enters License and Collaboration Agreement with ApolloBio To Develop and Commercialize VGX-3100 in …Markets Insider
Inovio revamps China deal; nets $23M upfront paymentPhiladelphia Business Journal
Frisco Fastball
all 40 news articles »

Gene therapy for inherited blindness sets precedent: $850000 price tag
Washington Post
A landmark gene therapy to treat a rare, inherited form of blindness will cost $850,000 — a price tag so daunting that its maker will offer health insurers partial rebates if the drug doesn’t work and is seeking to pilot an installment payment option …
Spark Therapeutics Sets Price Of Blindness-Curing Gene Therapy At $850000Forbes
A US drugmaker offers to cure rare blindness for $850000CNBC
Price Tag on Gene Therapy for Rare Form of Blindness: $850KU.S. News & World Report
STAT –Endpoints News
all 23 news articles »

Price tag on gene therapy for rare form of blindness: $850K …
Financial Post
FILE – In this Oct. 4, 2017, file photo, Dr. Albert Maguire, right, checks the eyes of Misa Kaabali, 8, at the Children’s Hospital of Philadelphia. Misa was 4-years-old when he received his gene therapy treatment. The first-of-its kind genetic …
Spark Therapeutics Sets Price Of Blindness-Treating Gene Therapy At $850000Forbes
Spark Therapeutics Announces First-of-their-kind Programs to Improve Patient Access to LUXTURNA™ (voretigene …Spark Therapeutics Inc.
A US drugmaker offers to cure rare blindness for $850000CNBC

all 122 news articles »

Sangamo partners with Pfizer to develop gene therapy for ALS
Reuters
The agency last month approved Spark Therapeutics Inc’s treatment for a rare form of blindness, marking the first approval of a gene therapy for an inherited disease. Under the terms of the deal, Sangamo will receive a $12 million upfront payment from …
Sangamo, Pfizer Collaborate On Zinc Finger Protein Gene Therapy For ALSNasdaq
Sangamo teams up with Pfizer to develop gene therapy to treat ALS; shares ahead 4% premarketSeeking Alpha
Sangamo, Pfizer to Develop Gene Therapy for Neurodegenerative DisordersFox Business
Endpoints News
all 5 news articles »